.35 semaglutide GLP-1 users to make up 35% of food and beverage sales by 2030: report Explainer: What's behind the scramble

But rapidly emerging data about its effectiveness for other health conditions is likely to further expand its use in future years

Regular TSH monitoring helps separate thyroid-related symptoms from medication adjustment effects

And so I think that is why a lot of our employers are interested in in this particular strategy to, again, have guardrails, have some cost containment around these products because the unmitigated use is just not sustainable in terms of a cost and budget impact

Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome

Self-Funded Employer Plans Check with HR Many large companies pay for healthcare themselves (this is called "self-funded")

[1] [2] Clinical studies suggest that tirzepatide may reduce energy intake, though the extent varies among individuals and tends to be most notable during initial therapy